Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

The Journal of antimicrobial chemotherapy - 1 May 2012

Sirgel Frederick A, Warren Robin M, Streicher Elizabeth M, Victor Thomas C, van Helden Paul D, Böttger Erik C

Abstract excerpt

OBJECTIVES: To compare mutations in the quinolone resistance-determining region of the gyrA gene and flanking sequences with the MICs of ofloxacin and moxifloxacin for Mycobacterium tuberculosis. METHODS: The presence of mutations in 177 drug-resistant M. tuberculosis isolates was determined by D...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Aza Compounds
Share to DNA Gyrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluoroquinolones

Share to Moxifloxacin

Share to Mycobacterium tuberculosis

Share to Ofloxacin

Share to Quinolines

Source

Identifiers

PMID: 22357804
DOI: 10.1093/jac/dks033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22357804-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.PMID 22357804Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.Semantic proximity Read ↗

Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.Semantic proximity Read ↗

Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.Semantic proximity Read ↗

Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.Semantic proximity Read ↗

Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance.Semantic proximity Read ↗

Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.Semantic proximity Read ↗

Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis.Semantic proximity Read ↗

Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.Semantic proximity Read ↗

Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.Semantic proximity Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patientsSemantic proximity Read ↗

Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.Semantic proximity Read ↗

Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.